# Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism

> **NCT02585713** · PHASE3 · COMPLETED · sponsor: **Academic and Community Cancer Research United** · enrollment: 300 (actual)

## Conditions studied

- Cerebral Vein Thrombosis
- Deep Vein Thrombosis
- Gonadal Thrombosis
- Hepatic Thrombosis
- Malignant Neoplasm
- Mesenteric Thrombosis
- Metastatic Malignant Neoplasm
- Portal Vein Thrombosis
- Pulmonary Embolism
- Renal Vein Thrombosis
- Splenic Thrombosis
- Venous Thromboembolism

## Interventions

- **DRUG:** Apixaban
- **DRUG:** Dalteparin
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT02585713
- **Lead sponsor:** Academic and Community Cancer Research United
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-20
- **Primary completion:** 2018-04-02
- **Final completion:** 2019-12-24
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2020-08-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02585713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02585713, "Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02585713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*